CliffBio
small molecule

CASPOFUNGIN ACETATE

CASPOFUNGIN ACETATE

Loss of exclusivityDecember 2032latest FDA-listed patent expiry
CompanyFresenius Kabi →See this company's full patent-cliff portfolio

Drug detail

Brand nameCASPOFUNGIN ACETATE
Active ingredientCASPOFUNGIN ACETATE
Strength70MG/VIAL
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalDecember 2016
Marketing statusRX

Listed patents

PatentExpiresType
9636407December 2032product

More from Fresenius Kabi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

CASPOFUNGIN ACETATE patent cliff — loss of exclusivity December 2032 | CliffBio